However, apatinib, a vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor, has been shown to increase the infiltration of CD8+ T cells, reduce the recruitment of tumor-associated macrophages, and improve the effect of PD-1 inhibitors (Zhao et al., 2019). This evidence concerns the gene KDR and neoplasm.